About MindMed
MindMed is a company based in New York (United States) founded in 2019 by JR Rahn and Stephen L Hurst. The company has 74 employees as of December 31, 2024. MindMed has completed 1 acquisition, including HealthMode. MindMed offers products and services including MM120 ODT and MM402. MindMed operates in a competitive market with competitors including ATAI, QurAlis, COMPASS Pathways, Passage Bio and Harmony Biosciences, among others.
- Headquarter New York, United States
- Employees 74 as on 31 Dec, 2024
- Founders JR Rahn, Stephen L Hurst
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mind Medicine (Mindmed) Inc.
-
Annual Revenue
Not available
-
Net Profit
-$108.68 M (USD)-13.52as on Dec 31, 2024
-
EBITDA
-$103.39 M (USD)-13.99as on Dec 31, 2024
-
Latest Funding Round
$75 M (USD), Post-IPO
Mar 11, 2024
- Investors
-
Employee Count
74
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MindMed
MindMed is a publicly listed company on the NASDAQ with ticker symbol MNMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MindMed
MindMed offers a comprehensive portfolio of products and services, including MM120 ODT and MM402.
Investigational drug targeting Generalized Anxiety Disorder and Major Depressive Disorder.
Drug candidate for Autism Spectrum Disorder symptoms.
People of MindMed
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Advisor Team
16 people
Product Management Team
13 people
Software Development Team
6 people
Operations Team
6 people
Finance and Accounting
4 people
Legal and Compliance
3 people
Clinical Team
3 people
Unlock access to complete
Funding Insights of MindMed
Investors in MindMed
MindMed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Broadway Mining.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Copper and gold deposits are explored and mined by Broadway.
|
Locked | Locked | Locked |
Investor details for MindMed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MindMed
MindMed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include HealthMode.
Investment portfolio details for MindMed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based wearable devices for clinical trial data collection are provided.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for MindMed
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MindMed
Detailed financials for MindMed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mindmed Comparisons
Peer comparison for MindMed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MindMed
MindMed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, QurAlis, COMPASS Pathways, Passage Bio and Harmony Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for CNS rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
Detailed competitors of MindMed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mindmed
Complete news archive for MindMed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MindMed
MindMed was founded in 2019.
MindMed is headquartered in New York, United States. It is registered at New York, New York, United States.
Stephen L Hurst is the current CEO of MindMed. They have also founded this company.
As of Dec 31, 2024, the latest employee count at MindMed is 74.
MindMed was founded in 2019 and is headquartered in New York, United States. Psychedelic-based therapies are developed to address brain health disorders, including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Product candidates are advanced through rigorous scientific methods to target unmet patient needs. Research efforts span diverse therapeutic areas and mechanisms of action within the biotechnology sector.
MindMed's top competitors include Harmony Biosciences, QurAlis and Passage Bio.
MindMed offers MM120 ODT and MM402.
Yes, MindMed is publicly traded on NASDAQ under the ticker symbol MNMD.
MindMed has made 1 acquisition, including HealthMode.
MindMed has 1 investor. Key investors include Broadway Mining.
The ticker symbol of MindMed is MNMD on NASDAQ.